Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032510 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
A Phase 3 study, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,205
- Enrollment target
NCT03032510 is a Phase 3 study that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 1,205 participants.
The verdict
NCT03032510, a Phase 3 study, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,205 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
Interventions
- DRUG Placebo
- DRUG Eravacycline
- DRUG Levofloxacin
- DRUG Ertapenem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,205 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03032510
The ClinicalTrials.gov registry entry for NCT03032510 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tetraphase Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03032510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03032510 about?
NCT03032510 is a clinical study titled "Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections". The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).
What is the current status of trial NCT03032510?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,205 participants. The study started on 2017-01. Estimated completion is 2018-01.
What interventions are being tested in trial NCT03032510?
The interventions under investigation include: Placebo (DRUG), Eravacycline (DRUG), Levofloxacin (DRUG), Ertapenem (DRUG).
Who is sponsoring clinical trial NCT03032510?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.